Analysis of the Effect of Metoprolol Combined with Irbesartan in the Treatment of Chronic Heart Failure on Cardiac Function Levels
Objective To analyze the value of the effect of simultaneous administration of metoprolol,irbesartan in pa-tients with heart failure.Methods 100 cases of chronic heart failure patients treated in Liaocheng Fourth People's Hospital from June 2022 to June 2023 were randomly selected as the study objects.They were divided into two groups based on the random draw method,with 50 cases in each group.The control group was treated with irbesartan single drug,and the observation group was treated with irbesartan+metoprolol,and the treatment period was 3 months.The clinical efficacy,cardiac function indexes,6-minute Walking Test(6MWT)and the incidence of adverse drug reac-tions were compared between the two groups.Results The total effective rate of treatment in the observation group was 92.00%,which was higher than 74.00%in the control group,and the difference was statistically significant(x2=5.740,P<0.05).Before treatment,compared with the cardiac function indexes and 6MWT of the two groups of patients,the difference was not statistically significant(all P>0.05),after treatment,the left ventricular end-diastolic internal diam-eter and left ventricular end-systolic internal diameter of the observation group were lower than those of the control group,and the left ventricular ejection fraction and 6MWT were higher than those of the control group,and the differ-ences were statistically significant(all P<0.05).Comparing the incidence of adverse effects of treatment between the two groups,the difference was not statistically significant(P>0.05).Conclusion Using irbesartan+metoprolol as a drug regimen for the treatment of chronic heart failure can further enhance the clinical efficacy,promote the improve-ment of cardiac function and 6MWT,and possess good drug safety.
NETL
NSTL
万方数据
